FDA Approves Ekterly
FDA Approves Ekterly – Generic name: sebetralstat is a first-in-class oral, on-demand medication developed for the treatment of acute attacks in patients with hereditary angioedema (HAE) aged 12 years and older. It marks a significant advancement in HAE management, offering the first non-injectable option for immediate treatment of these potentially life-threatening swelling episodes.